Phreesia (NYSE:PHR) Stock Rating Lowered by Barclays

Phreesia (NYSE:PHR) was downgraded by analysts at Barclays from a “strong-buy” rating to a “hold” rating in a report released on Thursday,Zacks.com reports.

Several other research firms have also commented on PHR. Canaccord Genuity Group lowered their price objective on shares of Phreesia from $33.00 to $22.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. BMO Capital Markets lowered their price objective on shares of Phreesia from $32.00 to $14.00 and set an “outperform” rating for the company in a research note on Tuesday, March 31st. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $16.00 price objective (down from $24.00) on shares of Phreesia in a research note on Tuesday, March 31st. Needham & Company LLC lowered their price objective on shares of Phreesia from $35.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Phreesia in a research note on Wednesday, January 28th. Eleven investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Phreesia Trading Up 0.1%

NYSE PHR opened at $8.78 on Thursday. The firm has a 50 day simple moving average of $9.94 and a 200-day simple moving average of $14.53. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.53 and a current ratio of 1.53. Phreesia has a one year low of $7.77 and a one year high of $32.76. The firm has a market cap of $533.29 million, a price-to-earnings ratio of 292.57 and a beta of 0.89.

Phreesia (NYSE:PHR) last posted its quarterly earnings data on Monday, March 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.05). Phreesia had a net margin of 0.48% and a return on equity of 3.23%. The business had revenue of $127.07 million during the quarter, compared to analysts’ expectations of $126.75 million. During the same period in the previous year, the business posted ($0.11) EPS. The company’s revenue for the quarter was up 15.9% compared to the same quarter last year. Equities research analysts anticipate that Phreesia will post 0.28 EPS for the current fiscal year.

Insider Activity

In related news, General Counsel Allison C. Hoffman sold 14,483 shares of Phreesia stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $8.07, for a total value of $116,877.81. Following the completion of the transaction, the general counsel owned 163,485 shares in the company, valued at $1,319,323.95. The trade was a 8.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider David Linetsky sold 8,332 shares of Phreesia stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $8.07, for a total transaction of $67,239.24. Following the completion of the transaction, the insider owned 224,056 shares of the company’s stock, valued at $1,808,131.92. This represents a 3.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 50,493 shares of company stock worth $461,983 over the last three months. Insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in PHR. Pale Fire Capital SE purchased a new position in Phreesia in the first quarter worth approximately $72,481,000. Granahan Investment Management LLC raised its holdings in Phreesia by 73.8% during the fourth quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company’s stock worth $40,601,000 after purchasing an additional 1,018,987 shares in the last quarter. Prosight Management LP acquired a new stake in Phreesia during the fourth quarter worth approximately $16,533,000. Millennium Management LLC raised its holdings in Phreesia by 730.7% during the third quarter. Millennium Management LLC now owns 1,064,132 shares of the company’s stock worth $25,028,000 after purchasing an additional 936,033 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new stake in Phreesia during the fourth quarter worth approximately $15,213,000. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Trending Headlines about Phreesia

Here are the key news stories impacting Phreesia this week:

• Negative Sentiment: Multiple law firms, including Rosen Law Firm, Faruqi & Faruqi, Pomerantz, Bragar Eagel & Squire, Gross Law Firm, Robbins LLP, and Gainey McKenna & Egleston, announced or promoted class-action lawsuits against Phreesia, alleging potential securities fraud tied to the period from May 8, 2025 through March 30, 2026. Article Title
• Negative Sentiment: The lawsuits and related investor alerts may increase legal costs, management distraction, and uncertainty around prior disclosures, which can weigh on investor sentiment toward the stock. Article Title
• Neutral Sentiment: Phreesia’s latest quarterly results were mixed: revenue came in slightly above expectations, but EPS missed consensus, which may still be influencing how investors view the company’s fundamentals.
• Neutral Sentiment: Despite the recent news flow, analysts previously remained constructive overall, with several Buy/Outperform ratings and a median price target above the current share price, suggesting some longer-term optimism remains.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.